June 2, 2017 10:59 AM EDT

Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122

Emma Yasinski

→ Minerva Neurosciences saw its shares $NERV jump on Thursday, after it announced revised terms to its collaboration with J&J on its orexin 2 receptor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122

Emma Yasinski

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Min­er­va shares jump as J&J hands over $30M, re­vis­es in­som­nia drug pact; Iroko lays off 122

Emma Yasinski

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Minerva shares jump as J&J hands over $30M, revises insomnia drug pact; Iroko lays off 122

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?